TRICIDA INC (TCDA)
US89610F1012 - Common Stock
TRICIDA INC
NASDAQ:TCDA (1/23/2023, 7:00:00 PM)
After market: 0.084 -0.02 (-22.22%)0.108
-0.01 (-10%)
Company Profile
Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The firm's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.
Company Info
TRICIDA INC
7000 Shoreline Court, Suite 201
South San Francisco CALIFORNIA 94080
P: 14154297800.0
CEO: Gerrit Klaerner
Employees: 57
Website: https://www.tricida.com/
TCDA News
a year ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off Thursday with an overview of the biggest pre-market stock movers traders will want to keep an eye on!
a year ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!
TCDA Twits
Here you can normally see the latest stock twits on TCDA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
